The safety and the efficacy of iptacopan are now under investigation within large phase III trials in both PNH patients inadequately treated by C5 inhibitors (in a head‐to‐head randomization), as well as in untreated PNH patients. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.